Absolutely. Anyone dealing with low monocyte MBC will want to get their hands on Efti asap. Ethically, European regulators and the FDA regulators should release Efti into this patient group and expedite any further needed trials asap. It would be unacceptable and unethical for this to drag on for years before it is released. There is enough data already that shows Efti is safe.
Let’s see how this pans out in the next few months, we are sitting on a blockbuster, imo.
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-17
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 148547 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 51809 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |